Report adverse event
FAQ
Log In/Register
International
Bulgaria
CZECH REPUBLIC
Denmark
Finland
Latvia
Netherlands
Norway
Poland
Romania
Russia
Serbia
Slovakia
Slovenia
Spain
Sweden
Ukraine
Switzerland
Austria
Asean
About schizophrenia
Log in required
Local regulations restrict this content to healthcare professionals
Login
What is Schizophrenia?
Neurochemical basis of schizophrenia
What are negative symptoms?
The Challenge of Negative Symptoms in Schizophrenia
Diagnosis of schizophrenia
Diagnostic Tools
Diagnostic Tools
The Challenge of Diagnosing Negative Symptoms
Transdiagnostic tool
Treatment of schizophrenia
Burden of schizophrenia and negative symptoms
Log in required
Local regulations restrict this content to healthcare professionals
Login
Treating Negative Symptoms of Schizophrenia
Our Product
Log in required
Local regulations restrict this content to healthcare professionals
Login
Log in required
Local regulations restrict this content to healthcare professionals
Login
Mode of Action
The Mechanism of Action of Our Product
Log in required
Local regulations restrict this content to healthcare professionals
Login
Clinical Data
Efficacy
Our Product in patients with acute exacerbation of schizophrenia
Cariprazine in the Long-Term Treatment of Schizophrenia
Cariprazine Controls Negative Symptoms in Schizophrenia
Controlling Everyday Functioning with Cariprazine
Cariprazine's Effects on Primary and Secondary Negative Symptoms: The Pseudospecificity Problem
Safety
Akathisia Guide
The Safety and Tolerability Profile of Our Product
The Management of Akathisia
Our product and Weight Gain
Log in required
Local regulations restrict this content to healthcare professionals
Login
Prescribing Our Product
Initiating
Switching
Dosing
Cariprazine Dosing Guide
Polypharmacy
Polipharmacy Guide
Experience our product
Log in required
Local regulations restrict this content to healthcare professionals
Login
Reagila Patients
PATIENT SERIES: ACUTE PATIENTS
PATIENT SERIES: PATIENTS WITH NEGATIVE SYMPTOMS
PATIENT SERIES: THE SUBACUTE PATIENT
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – LACK OF EFFICACY
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – SAFETY ISSUES
Log in required
Local regulations restrict this content to healthcare professionals
Login
Patient cases
A clinical case of patient with early psychosis treated with cariprazine
Our product add-on in inadequate clozapine response: a case study
Case Study of a Drug-Naïve Female Patient Treated With Cariprazine
Our product add-on in inadequate clozapine response: another case study
Early psychosis treated with cariprazine: a case study
Patient Cases Series
Education & Resources
Log in required
Local regulations restrict this content to healthcare professionals
Login
Interviews & video materials
Antagonist or partial agonist – which one is the best drug?
The role of partial agonists in schizophrenia treatment: managing the clinical aspects - ECNP 2020
Treatment with our product to address schizophrenia needs - ECNP 2020
Scientific Article Summaries
Literature Review
Schizophrenia: negative symptoms
Cariprazine in the treatment of schizophrenia in clinical research and the real-world
The safety of recently developed antipsychotics
Dose-response in antipsychotics
Dosing antipsychotics in acute schizophrenia
Clinical guide for treating negative symptoms in schizophrenia
A skizofrénia negatív tüneti dimenzióinak patofiziológiai megértése
Validation of the PANSS in two-factor negative symptom distinction
Benefits of Antipsychotic Polypharmacy in Schizophrenia Maintenance Therapy
Schizophrenia: Is It All Down To Your Genes?
Causal Relationship Between Cognitive Deficit and Risk of Schizophrenia
Connection Between Inflammation and Schizophrenia?
Potential benefits of using eHealth in the management of schizophrenia
Markers of Inflammation and Infection in Schizophrenia
The Role of Cannabis in Treatment-Resistant Schizophrenia
Childhood Behaviour to Predict Psychosis-Spectrum Diagnoses in Adulthood
Suicide Prevention
Investigating the Stigma Around Mental Health and When People Seek Professional Advice to Control Early Psychiatric Symptoms
Reversal of Schizophrenia Memory Deficits
Switching Antipsychotic Medications in Schizophrenia: Why, When and How?
Can Substance Abuse Cause Psychosis?
The Epstein–Barr Virus and Schizophrenia
Antipsychotic polypharmacy and non-adherence
How to provide care for people with schizophrenia: challenges posed by the covid-19 pandemic
Biomarker Signature of Negative Symptoms
The hyperacute schizophrenic patient
How physical exercise helps individuals with schizophrenia
COVID-19 and mental health
COVID-19 and suicidality
COVID-19 and the risk of developing mental health problems
COVID-19 and schizophrenia
Association between COVID-19 and psychiatric illnesses – a summary of different articles
Downloadable
Akathisia Guide
Cariprazine Dosing Guide
Polipharmacy Guide
Dual Disorder Guide
Transdiagnostic tool
pen-and-paper version
The Candid Book
Understanding the Dimensions of Schizophrenia
Psychiatrist’s view: What are the dimensions of schizophrenia?
Events
Log in required
Local regulations restrict this content to healthcare professionals
Login
Log in required
Local regulations restrict this content to healthcare professionals
Login
SCHIZOPHRENIA AWARENESS WEEK
ECNP Congress
2021
Evolving use of digital tools in schizophrenia assessment
Bridging adherence to long-term functioning in schizophrenia
The Schizophrenia Polypharmacy Quiz
Cognitive impairment in schizophrenia: the "big" unmet need
Living with schizophrenia after the covid-19 pandemic
2020
Symposium report: our product in schizophrenia
Can eating better improve people’s mental health?
Smartphone apps promise to support psychiatric practice
Exploring synaptic dysfunction in schizophrenia
Improving detection of young people at risk of psychoses
Exploring the druggable genome across psychiatric disorders
Managing psychosis in pregnancy still challenging
Early neurodevelopmental trauma induces adult psychosis
WFSBP 2021 Highlights
Towards digital-based care of schizophrenia: Where are we heading?
Cognitive impairment and negative symptoms in schizophrenia
Cariprazine as a broad-spectrum treatment
EPA Congress
2023
DEBATE - WE NEED TO ABANDON THE CURRENT SCHIZOPHRENIA CONSTRUCT
PANEL DISCUSSION - PHYSICAL ACTIVITY IN PEOPLE WITH SEVERE MENTAL DISORDERS: MYTH OR REALITY?
2022
SYMPOSIUM: TRANSDIAGNOSTIC PSYCHIATRY: THE NEW TREND
DOSING STRATEGIES FOR THE TREATMENT OF SCHIZOPHRENIA: A FOCUS ON CARIPRAZINE
2021
EPA SYMPOSIUM: Cariprazine throughout the stages of schizophrenia
Symposium: Polypharmacy in schizophrenia: A rational approach
LIVE-DEBATE: Should schizoaffective disorder be diagnosed cross-sectionally (ICD-11) instead of longitudinally (DSM-5)?
Cognitive Remediation in Schizophrenia
EPA SYMPOSIUM: Predicting outcomes in psychosis
LIVE ECP SYMPOSIUM: Personalised psychiatry in schizophrenia
LIVE: Personalising primary psychosis management
Early Intervention in Psychoses
Improving Real-life Functioning in People with Schizophrenia
Interventions, Neuroanatomy and Cognition in Psychoses
2020
Antipsychotic monotherapy or polypharmacy: what’s the evidence?
Best of 2019 article overview of research in schizophrenia
Integrated treatment for people with schizophrenia
Metacognition key to improving functioning in schizophrenia?
NEXT
How to provide care for people with schizophrenia: challenges posed by the COVID-19 pandemic
Beyond pharmacotherapy: Negative symptoms in the current literature
Cariprazine as a broad-spectrum treatment for patients with schizophrenia
Pharmacological treatment of negative symptoms in schizophrenia
Webinars
Psychiatry Update Webinars
Functioning and recovery in schizophrenia
Visit this section
About schizophrenia
What is Schizophrenia?
Neurochemical basis of schizophrenia
What are negative symptoms?
The Challenge of Negative Symptoms in Schizophrenia
Diagnosis of schizophrenia
Diagnostic Tools
Diagnostic Tools
The Challenge of Diagnosing Negative Symptoms
Transdiagnostic tool
Treatment of schizophrenia
Burden of schizophrenia and negative symptoms
Treating Negative Symptoms of Schizophrenia
Our Product
Mode of Action
The Mechanism of Action of Our Product
Clinical Data
Efficacy
Our Product in patients with acute exacerbation of schizophrenia
Cariprazine in the Long-Term Treatment of Schizophrenia
Cariprazine Controls Negative Symptoms in Schizophrenia
Controlling Everyday Functioning with Cariprazine
Cariprazine's Effects on Primary and Secondary Negative Symptoms: The Pseudospecificity Problem
Safety
Akathisia Guide
The Safety and Tolerability Profile of Our Product
The Management of Akathisia
Our product and Weight Gain
Prescribing Our Product
Initiating
Switching
Dosing
Cariprazine Dosing Guide
Polypharmacy
Polipharmacy Guide
Experience our product
Reagila Patients
PATIENT SERIES: ACUTE PATIENTS
PATIENT SERIES: PATIENTS WITH NEGATIVE SYMPTOMS
PATIENT SERIES: THE SUBACUTE PATIENT
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – LACK OF EFFICACY
PATIENT SERIES: PATIENTS WITH THERAPEUTIC COMPROMISE – SAFETY ISSUES
Patient cases
A clinical case of patient with early psychosis treated with cariprazine
Our product add-on in inadequate clozapine response: a case study
Case Study of a Drug-Naïve Female Patient Treated With Cariprazine
Our product add-on in inadequate clozapine response: another case study
Early psychosis treated with cariprazine: a case study
Patient Cases Series
Education & Resources
Interviews & video materials
Antagonist or partial agonist – which one is the best drug?
The role of partial agonists in schizophrenia treatment: managing the clinical aspects - ECNP 2020
Treatment with our product to address schizophrenia needs - ECNP 2020
Scientific Article Summaries
Literature Review
Schizophrenia: negative symptoms
Cariprazine in the treatment of schizophrenia in clinical research and the real-world
The safety of recently developed antipsychotics
Dose-response in antipsychotics
Dosing antipsychotics in acute schizophrenia
Clinical guide for treating negative symptoms in schizophrenia
A skizofrénia negatív tüneti dimenzióinak patofiziológiai megértése
Validation of the PANSS in two-factor negative symptom distinction
Benefits of Antipsychotic Polypharmacy in Schizophrenia Maintenance Therapy
Schizophrenia: Is It All Down To Your Genes?
Causal Relationship Between Cognitive Deficit and Risk of Schizophrenia
Connection Between Inflammation and Schizophrenia?
Potential benefits of using eHealth in the management of schizophrenia
Markers of Inflammation and Infection in Schizophrenia
The Role of Cannabis in Treatment-Resistant Schizophrenia
Childhood Behaviour to Predict Psychosis-Spectrum Diagnoses in Adulthood
Suicide Prevention
Investigating the Stigma Around Mental Health and When People Seek Professional Advice to Control Early Psychiatric Symptoms
Reversal of Schizophrenia Memory Deficits
Switching Antipsychotic Medications in Schizophrenia: Why, When and How?
Can Substance Abuse Cause Psychosis?
The Epstein–Barr Virus and Schizophrenia
Antipsychotic polypharmacy and non-adherence
How to provide care for people with schizophrenia: challenges posed by the covid-19 pandemic
Biomarker Signature of Negative Symptoms
The hyperacute schizophrenic patient
How physical exercise helps individuals with schizophrenia
COVID-19 and mental health
COVID-19 and suicidality
COVID-19 and the risk of developing mental health problems
COVID-19 and schizophrenia
Association between COVID-19 and psychiatric illnesses – a summary of different articles
Downloadable
Akathisia Guide
Cariprazine Dosing Guide
Polipharmacy Guide
Dual Disorder Guide
Transdiagnostic tool
pen-and-paper version
The Candid Book
Understanding the Dimensions of Schizophrenia
Psychiatrist’s view: What are the dimensions of schizophrenia?
Events
SCHIZOPHRENIA AWARENESS WEEK
ECNP Congress
2021
Evolving use of digital tools in schizophrenia assessment
Bridging adherence to long-term functioning in schizophrenia
The Schizophrenia Polypharmacy Quiz
Cognitive impairment in schizophrenia: the "big" unmet need
Living with schizophrenia after the covid-19 pandemic
2020
Symposium report: our product in schizophrenia
Can eating better improve people’s mental health?
Smartphone apps promise to support psychiatric practice
Exploring synaptic dysfunction in schizophrenia
Improving detection of young people at risk of psychoses
Exploring the druggable genome across psychiatric disorders
Managing psychosis in pregnancy still challenging
Early neurodevelopmental trauma induces adult psychosis
WFSBP 2021 Highlights
Towards digital-based care of schizophrenia: Where are we heading?
Cognitive impairment and negative symptoms in schizophrenia
Cariprazine as a broad-spectrum treatment
EPA Congress
2023
DEBATE - WE NEED TO ABANDON THE CURRENT SCHIZOPHRENIA CONSTRUCT
PANEL DISCUSSION - PHYSICAL ACTIVITY IN PEOPLE WITH SEVERE MENTAL DISORDERS: MYTH OR REALITY?
2022
SYMPOSIUM: TRANSDIAGNOSTIC PSYCHIATRY: THE NEW TREND
DOSING STRATEGIES FOR THE TREATMENT OF SCHIZOPHRENIA: A FOCUS ON CARIPRAZINE
2021
EPA SYMPOSIUM: Cariprazine throughout the stages of schizophrenia
Symposium: Polypharmacy in schizophrenia: A rational approach
LIVE-DEBATE: Should schizoaffective disorder be diagnosed cross-sectionally (ICD-11) instead of longitudinally (DSM-5)?
Cognitive Remediation in Schizophrenia
EPA SYMPOSIUM: Predicting outcomes in psychosis
LIVE ECP SYMPOSIUM: Personalised psychiatry in schizophrenia
LIVE: Personalising primary psychosis management
Early Intervention in Psychoses
Improving Real-life Functioning in People with Schizophrenia
Interventions, Neuroanatomy and Cognition in Psychoses
2020
Antipsychotic monotherapy or polypharmacy: what’s the evidence?
Best of 2019 article overview of research in schizophrenia
Integrated treatment for people with schizophrenia
Metacognition key to improving functioning in schizophrenia?
NEXT
How to provide care for people with schizophrenia: challenges posed by the COVID-19 pandemic
Beyond pharmacotherapy: Negative symptoms in the current literature
Cariprazine as a broad-spectrum treatment for patients with schizophrenia
Pharmacological treatment of negative symptoms in schizophrenia
Webinars
Psychiatry Update Webinars
Functioning and recovery in schizophrenia
Report adverse event
International
Bulgaria
CZECH REPUBLIC
Denmark
Finland
Latvia
Netherlands
Norway
Poland
Romania
Russia
Serbia
Slovakia
Slovenia
Spain
Sweden
Ukraine
Switzerland
Austria
Asean
website for members of the public
Log In | Register
Healthcare professionals
Public
DocCheck Login
You are now leaving the site and will be re-directed to an external website.
Accept
Cancel
Showing
0
result(s).
Please log in to see
0
more result(s).